High Precision Vial Liquid Filling Machine for Monoclonal Antibody Production with Self Flow Filling System, GMP Compliant

High Precision Vial Liquid Filling Machine for Monoclonal Antibody Production with Self Flow Filling System, GMP Compliant

Revolutionize Biopharmaceutical Manufacturing with Our Advanced Vial Liquid Filling Machine
In the rapidly evolving field of biopharmaceuticals, precision and sterility are non-negotiable. Our vial liquid filling machine is engineered to meet the exacting demands of monoclonal antibody production, a cutting-edge therapy for cancer, autoimmune diseases, and infectious diseases. Designed for 2-100ml vials, this machine integrates aseptic filling technology and GMP-compliant workflows to ensure every dose meets global regulatory standards.

Key Innovations for Modern Labs & Facilities:
✅ Ultra-Clean Aseptic Design: Built with 316L stainless steel and ISO 5-grade laminar airflow, our machine eliminates contamination risks during filling, critical for sensitive biologics like monoclonal antibodies.
✅ Adaptive Capacity Control: Seamlessly switch between 2ml pilot batches and 100ml commercial-scale production with modular needle configurations (6-12 heads), minimizing downtime and maximizing flexibility.
✅ Smart Precision Dosing: Achieve ±0.5% filling accuracy using ceramic piston pumps and servo-driven controls, ensuring consistent antibody concentrations for therapeutic efficacy.
✅ Energy-Efficient Performance: Operates at 300-600W with PLC + touchscreen automation, reducing manual intervention while optimizing power consumption for sustainable production.

Why Choose Us?
Monoclonal antibodies require temperature-sensitive handling and traceability. Our vial liquid filling machine features:

• Real-time data logging for batch records and compliance audits.
• CIP/SIP systems for rapid cleaning and sterilization.
• Anti-drip nozzles and nitrogen blanketing to protect oxygen-sensitive formulations.

Ideal For:
Biotech startups scaling up R&D, CMOs serving global clinical trials, and pharma giants aiming for high-yield, low-waste production.